ANI Pharmaceuticals | ANIP - Cash And Equivalent


ANI Pharmaceuticals reported $311.18M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Assertio Holdings USD 38.5M 8.59M Sep/2025
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Canopy Growth CAD 371.32M 73.26M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Hikma Pharmaceutical USD 236M 48M Jun/2025
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Omeros USD 1.9M 2.36M Jun/2025
Perrigo USD 531.6M 99.5M Dec/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025